Monopar Therapeutics (MNPR) Return on Equity (2018 - 2025)

Monopar Therapeutics has disclosed Return on Equity across 8 years of filings, most recently posting 0.0% for Q4 2025.

• Return on Equity for Q4 2025 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.0% (changed 0.0% YoY), and the FY2024 annual result was 0.01%, up 1.0% from the prior year.
• Return on Equity came in at 0.0% for Q4 2025 at Monopar Therapeutics, up from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q4 2025 to a low of 0.03% in Q3 2023.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.01%.
• Across the five-year window, Return on Equity slipped 2 bps in 2023 and grew 2 bps in 2024, its largest moves.
• Monopar Therapeutics' Return on Equity stood at 0.0% in 2021, then plunged by 323 bps to 0.02% in 2022, then soared by 42 bps to 0.01% in 2023, then surged by 86 bps to 0.0% in 2024, then soared by 62 bps to 0.0% in 2025.
• The last three Return on Equity figures came in at 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025), per Business Quant data.